Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the drug ambroxol hydrochloride in patients with Parkinsons disease PD to see if it can slow disease progression and to assess its safety and tolerability. This trial is a Phase IIIa study conducted in the UK, involving patients diagnosed with PD within the past 7 years. Ambroxol hydrochloride is already licensed for respiratory conditions, and this study aims to explore its potential benefits in PD treatment. Participants will be randomly assigned to receive either ambroxol hydrochloride or a matching placebo in a double-blind manner for 104 weeks. The dosing starts at 420mg daily for the first 5 days, increases to 840mg daily for days 6-10, and then 1260mg daily for the remainder of the blinded treatment period. After this, all participants enter a 26-week open-label extension phase, during which they will receive ambroxol hydrochloride at the same dosing schedule. An optional sub-study involves lumbar punctures at two time points to measure drug levels and related biomarkers in the cerebrospinal fluid. Throughout the study, participants will attend regular visits for assessments including the Movement Disorder Society Unified Parkinsons Disease Rating Scale MDS-UPDRS and cognitive tests. Safety will be monitored through vital signs and blood tests at multiple time points. The primary measure is the change in MDS-UPDRS score from baseline to week 104. Secondary outcomes include motor and non-motor symptoms, quality of life, and symptom severity. The total participation lasts approximately 130 weeks, including the extension phase, with detailed monitoring and data collection.
Actively Recruiting
This research aims to collect long-term safety and disease progression data on patients diagnosed with atypical hemolytic-uremic syndrome aHUS, including those treated or untreated with the drugs eculizumab or ravulizumab. The study is observational and involves multiple centers and countries, focusing on real-world information after these treatments have been marketed. Participants include patients of any age diagnosed with aHUS, regardless of whether they have identified complement genetic variants or antibodies. The study gathers data without administering new treatments, monitoring patients who may or may not have received eculizumab or ravulizumab. The registry collects information over extended periods to understand safety events and disease course. During the study, researchers track safety-related events over 10 years and the timing of these events within 5 years. Data collection involves reviewing patient health status and disease progression without altering their usual care. The study relies on informed consent and may include minors with appropriate assent. Participation duration varies, with continuous observation to gather comprehensive post-marketing safety data.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of whole-body hypothermia for newborn babies with mild hypoxic ischaemic encephalopathy. This phase III randomised controlled trial aims to determine whether cooling the whole body to 33.5.5C within six hours after birth and continuing for 72 hours improves cognitive development at around two years of age compared with maintaining normal body temperature. The study also seeks to assess the economic value of cooling therapy for mild encephalopathy within the healthcare system. Babies born at or after 36 weeks with signs of birth asphyxia or acidosis will be randomly assigned to receive either whole-body hypothermia or targeted normothermia. Cooling will be applied using a servo-controlled machine in neonatal intensive care units, maintaining a rectal temperature of about 33.5C for 72 hours. The control group will have their body temperature kept at normal levels 37C for the first 80 hours, with any fever carefully treated. Babies born at non-cooling centers will be transferred to specialized units for treatment. During the study, participants will undergo brain monitoring, MRI scans before discharge, and follow-up developmental assessments at 24 months using the Bayley Scales of Infant and Toddler Development IV. Additional evaluations will include neurological exams, motor function assessments, vision and hearing tests, and parent-completed questionnaires. Researchers will collect detailed clinical data from birth through hospital stay, aiming to compare cognitive outcomes and safety measures between the two groups over the study period.
Actively Recruiting
Researchers are evaluating a new combination of three drugsIsatuximab, Iberdomide, and Dexamethasonein adults with intermediate or high risk smouldering myeloma. This early form of myeloma can progress slowly to active multiple myeloma, and the study aims to see if this drug combination can prevent or delay disease progression while being tolerated and accepted by patients. Participants will receive treatment over two years, divided into 26 cycles of 28 days each, organized into three stages induction cycles 1-4, consolidation cycles 5-13, and maintenance cycles 14-26. Isatuximab is given subcutaneously via a medical device with varying frequency across stages, while Iberdomide and Dexamethasone are administered orally with specific dosing schedules throughout the treatment period. During the study, participants will be regularly monitored for treatment delivery and effectiveness, including response rates and safety. Researchers will assess progression-free survival, disease biomarkers, adverse events, and patient-reported outcomes through questionnaires and laboratory tests. Follow-up extends up to 5.5 years for long-term outcomes, with safety monitoring continuing for six months after treatment ends.
Actively Recruiting
This research aims to compare two standard care approaches in very premature infants born before 30 weeks to see if withholding enteral feeds around the time of blood transfusion reduces the risk of Necrotizing Enterocolitis NEC, a serious intestinal disease. NEC can severely damage the bowel and has a high risk of death or long-term health problems. The study involves infants from neonatal intensive care units in Canada and the UK and evaluates if withholding or continuing feeds during transfusion affects outcomes. The study randomly assigns infants to one of two groups one where all enteral feeds are stopped for 4 hours before, during, and after packed red cell transfusion and another where feeding continues as usual throughout the transfusion period. Infants will remain on their assigned feeding strategy until reaching 34 weeks and 6 days gestational age. During feed withholding, hydration and blood sugar are maintained by parenteral nutrition or intravenous glucose according to local practice. Participants will be monitored from randomization until 40 weeks postmenstrual age for the development and severity of NEC, death, infections, nutritional support duration, growth, and other health outcomes. Researchers will track feeding practices, transfusions, and clinical events, with long-term follow-up until discharge from the hospital. The study intends to identify which feeding approach during transfusion might better prevent NEC in these vulnerable infants.